Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Type
ArticleAuthor/s
Rogiers, Aljosjada Silva, Ines Pires
Tentori, Chiara
Tondini, Carlo Alberto
Grimes, Joseph M
Trager, Megan H
Nahm, Sharon
Zubiri, Leyre
Manos, Michael
Bowling, Peter
Elkrief, Arielle
Papneja, Neha
Vitale, Maria Grazia
Rose, Apri
Abstract
BACKGROUND: Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on tBACKGROUND: Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on t
See less
See less
Date
2021Share